58743-80-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Bromophenyl)-4-ethoxybenzene is used as an intermediate in the synthesis of various pharmaceuticals due to its unique structure and reactivity. Its ability to be modified and incorporated into more complex molecules makes it a valuable component in drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(4-Bromophenyl)-4-ethoxybenzene is used as a precursor for the development of new agrochemicals. Its structural properties allow for the creation of compounds that can be applied in pest control and crop protection.
Used in Material Science:
1-(4-Bromophenyl)-4-ethoxybenzene is also utilized in material science for the production of specific materials with desired properties. Its versatility in organic synthesis enables the creation of materials with tailored characteristics for various applications.
Safety Note:
Given the potential reactivity and toxicity of 1-(4-Bromophenyl)-4-ethoxybenzene, it is crucial to adhere to proper handling and storage procedures when working with 1-(4-Bromophenyl)-4-ethoxybenzene to ensure safety in research and industrial settings.

Upstream product

• 29558-77-8 4-bromo-4'-hydroxybiphenyl 
• 75-03-6 ethyl iodide 
• 589-87-7 1,4-bromoiodobenzene 
• 22237-13-4 (4-ethoxyphenyl)boronic acid 
• 584-08-7 potassium carbonate 
• 74-96-4 ethyl bromide 
• 64-67-5 diethyl sulfate 

Downstream Products

• 182344-29-2 4'-ethoxybiphenyl-4-yl boronic acid 
• 1192136-38-1 (S)-((3aS,5S,6R,6aS)-6-(tert-butyldimethylsilyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(4'-ethoxybiphenyl-4-yl)methanol 
• 58743-78-5 4'-ethoxybiphenyl-4-carbonitrile 

Relevant academic research and scientific papers

C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents

A series of highly active C-aryl glucoside SGLT2 inhibitors containing a biphenyl motif were designed and synthesized for biological evaluation. Among the compounds tested, compound 16l demonstrated high inhibitory activity against SGLT2 (IC50 = 1.9 nM) with an excellent pharmacokinetic profile. Further study indicated that the in vivo efficacy of compound 16l was comparable to that of dapagliflozin, suggesting that further development would be worthwhile.

Synthesis and property of liquid crystalline 4-alkoxyl-4″-cyano-p-terphenyls

The synthesis of some new 4-alkoxyl-4″-cyano-p-terphenyls is described. The preliminary characterization by means of polarized optical microscopy, differential scanning calorimetry and X-ray diffraction shows that all these compounds are thermotropically liquid-crystalline and can form both the nematic and smectic mesophases.

SUBSTITUTED CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS

Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula STR1 wherein each T is a substituent g roup; x is 0, 1, or 2; the group D represents STR2 the subscript "e" is 2 or 3; the group R 14 represents a variety of possible substituent groups of the cycloalkyl ring between D and G; the subscript "k" is 0-2; and the group G represents M, STR3 in which M represents--CO 2 H,--CON(R 11) 2, or--CO 2 R 12 ; and R 13 represents any of the side chains of the 19 noncyclic occurring amino acids. "

Biphenyl quinuclidines

Biphenylylquinuclidine compounds of the formula I: STR1 and pharmaceutically-acceptable salts thereof; wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 are joined together so that CR1 -CR2 is a double bond; and one or both ring A and ring B may be optionally unsubstituted or independently substituted by one or more substituents selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-?(1-6C)alkyl!amino, N-?(1-6C)alkyl!carbamoyl, N,N-di-?(1-6C)alkyl!carbamoyl, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl and halogeno-(1-6C)alkyl; are inhibitors of squalene synthase and are hence useful in treating diseases or medical conditions such as hypercholesterolemia, atherosclerosis and fungal diseases. Methods of using these compounds to treat such conditions, novel compounds, processes for making these compounds and pharmaceutical compositions containing them are claimed.